Ibrance Pfizer Australia Pty Ltd
Product name
Ibrance
Sponsor
Accepted date
Feb-2026
Active ingredients
palbociclib
Proposed indication
IBRANCE is proposed, in combination with anti-HER2 and endocrine therapies, for the maintenance treatment of adult patients with HR-positive, HER2-positive locally advanced or metastatic breast cancer following induction treatment.
IBRANCE is also proposed as a treatment for HR positive, HER2 positive breast cancer that is advanced or has spread. In this case, it is taken with anti-HER2 medicines and hormone therapy as a maintenance treatment.
IBRANCE is also proposed as a treatment for HR positive, HER2 positive breast cancer that is advanced or has spread. In this case, it is taken with anti-HER2 medicines and hormone therapy as a maintenance treatment.
Application type
C (new indication)
Publication date
Feb-2026